Spiceland CM, et al. - Researchers evaluated the outcomes of fidaxomicin therapy in patients with Clostridium difficile infection (CDI). No recurrences were noted among all patients with a first CDI episode, who responded to fidaxomicin. Individuals with prior CDI episodes (especially with more than 1 prior episode) were less likely to respond and more likely to recur. Findings revealed a greater clinical benefit of fidaxomicin earlier in the course of CDI.